Is 1-Month Dual Antithrombotic Therapy Enough After PCI?
Managing anticoagulation alongside antiplatelet therapy presents a continuous clinical dilemma. Dual antithrombotic therapy remains a cornerstone after percutaneous coronary intervention (PCI) in patients with atrial fibrillation. However, prolonged combination regimens substantially heighten bleeding risks. Recent evidence from the OPTIMA-AF trial evaluates whether clinicians can safely abbreviate this treatment strategy. Specifically, researchers investigated whether stopping antiplatelet therapy at one month compromises ischemic safety.
Trial Architecture and Evaluating Dual Antithrombotic Therapy
The OPTIMA-AF trial was an open-label, randomized controlled study conducted across 75 centers in Japan. Investigators enrolled 1,088 patients with atrial fibrillation who underwent contemporary PCI with intravascular imaging guidance. Notably, over 94% of participants had chronic coronary syndromes. The investigators randomly assigned participants to two distinct therapeutic arms. The intervention group received one month of dual antithrombotic therapy followed by direct oral anticoagulant (DOAC) monotherapy. In contrast, the control arm continued dual antithrombotic therapy for a full 12 months. The primary efficacy endpoint encompassed all-cause death or thromboembolic events at 12 months. Concurrently, the primary safety endpoint tracked major or clinically relevant non-major bleeding. Consequently, this trial provided robust real-world data regarding early antiplatelet cessation.
Key Efficacy and Safety Outcomes
The final analysis evaluated 1,079 patients and yielded striking clinical findings. First, one month of combination therapy met the criteria for noninferiority regarding primary efficacy. Thromboembolic events or death occurred in 5.4% of the 1-month group versus 4.3% in the 12-month group. Furthermore, the abbreviated regimen demonstrated marked superiority in bleeding outcomes. Major or clinically relevant nonmajor bleeding occurred in only 4.5% of short-course patients compared with 8.8% in the extended group. This difference represented a 50% relative risk reduction in hemorrhagic complications. In addition, fewer clinically relevant nonmajor bleeds drove this significant reduction in hemorrhagic risk. Therefore, early discontinuation of the P2Y12 inhibitor preserved thrombotic safety while offering a profound bleeding advantage.
Clinical Implications for Practice
These trial results deliver practical insights for cardiologists managing complex cardiovascular patients. Bleeding complications frequently compromise patient compliance and increase mortality. Consequently, minimizing dual treatment duration provides an immediate therapeutic advantage. However, clinicians must apply these findings cautiously. Nearly all patients in this trial presented with chronic coronary syndromes rather than acute presentations. Moreover, interventional cardiologists performed all stenting procedures under intravascular imaging guidance. Such imaging guidance optimizes stent expansion and reduces future stent thrombosis risks. Thus, while one month of dual therapy is attractive, high-risk acute coronary syndrome patients may still warrant personalized duration decisions. Overall, transitioning to single oral anticoagulation after 30 days represents an effective strategy for stable patients.
Frequently Asked Questions
Q1: What did the OPTIMA-AF trial determine regarding 1-month dual antithrombotic therapy?
The trial demonstrated that 1 month of dual antithrombotic therapy was noninferior to 12 months for preventing death or thromboembolic events. Furthermore, the 1-month regimen halved the rate of major or clinically relevant nonmajor bleeding.
Q2: Can clinicians extrapolate these findings to acute coronary syndrome patients?
Caution is necessary because approximately 94% of trial participants had chronic coronary syndromes. Therefore, physicians should carefully weigh individual ischemic versus bleeding risks before discontinuing antiplatelet therapy in acute coronary syndrome presentations.
Q3: What role did intravascular imaging play in this trial?
Operators performed all stent implantations with intravascular ultrasound or optical coherence tomography. Consequently, optimal stent apposition and expansion likely minimized early thrombosis, supporting the safety of early antiplatelet cessation.
References
- Mukherjee D et al. After PCI in AF, DAT for 1 mo was noninferior to 12 mo for mortality or thromboembolic events and reduced major or nonmajor bleeding. Ann Intern Med. 2026 Nov 03. doi: 10.7326/ANNALS-26-04074-JC. PMID: 42970808.
- Sotomi Y, Kozuma K, Higuchi Y, et al. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial. Lancet. 2026;408(10451):440-452.
- Raffo C, Giacoppo D, Capodanno D, Greco A. Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. J Clin Med. 2026;15(18):7298.
